What Does the Cardiologist Need to Know About SGLT2 Inhibitors?
Published: 25 August 2020
-
Views:
34
-
Likes:
7
-
Views:
34
-
Likes:
7
Overview
In this Educational Symposium from the e-SPACE Heart Failure Global Web-Conference, John McMurray, Mikhail Kosiborod and Avivit Cahn discuss historical data demonstrating the efficacy of SGLT2 inhibitors in HF patients with T2DM, look at data on the use of the agents in non-diabetics and other populations with HFrEF in regards to the DAPA-HF study; and assess how SGLT2 inhibitors should be incorporated within the context of existing therapies in the HFrEF landscape.
Education Objectives
- Revisit or Enhance Awareness of Historical Data Demonstrating the Efficacy of sglt2 Inhibitors With Regards to Hf Outcomes in Type 2 Diabetes Populations
- Explore the Recent Emergence of the SGLT2 Inhibitor Class in Non-Diabetes HF Populations and the Clinical Effects of Dapagliflozin Across a Broad Range of Patients With HF With Reduced Ejection Fraction (HfrEF) From the DAPA-HF Trial
- Strengthen Understanding of How to Use SGLT2 Inhibitors Safely and Effectively in HfrEF, and Within the Context of Existing Therapies in the HFrEF Landscape
More from this programme
Part 1
Welcome & Introductions
| 1 session | |
| Welcome & Introductions | Watch now |
Part 2
SGLT2 in Prevention of Heart Failure
Part 3
DAPA-HF ‘Deep Dive’
| 1 session | |
| DAPA-HF ‘Deep Dive’ | Watch now |
Part 4
Panel Discussion
| 1 session | |
| Panel Discussion | Watch now |
Faculty Biographies
John JV McMurray
Professor of Cardiology
Dr McMurray is Professor of Medical Cardiology and Deputy Director (Clinical) of the Institute of Cardiovascular and Medical Sciences and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.